Search

Author/Creator Wang, Michael L

1. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Issue 1 (January 2016)

Authors:
Wang, Michael L; Lee, Hun; Chuang, Hubert; Wagner-Bartak, Nicolaus; Hagemeister, Frederick; Westin, Jason; Fayad, Luis; Samaniego, Felipe; Turturro, Francesco; Oki, Yasuhiro; Chen, Wendy; Badillo, Maria; Nomie, Krystle; Rosa, Maria DeLa; Zhao, Donglu; Lam, Laura; Addison, Alicia; Zhang, Hui; Youn...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 1(2016:Feb.)
Page Start:
48
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Issue 3 (March 2022)

Authors:
Wang, Michael L; Jain, Preetesh; Zhao, Shuangtao; Lee, Hun Ju; Nastoupil, Loretta; Fayad, Luis; Ok, Chi Young; Kanagal-Shamanna, Rashmi; Hill, Holly A; Yao, Yixin; Hagemeister, Fredrick B; Westin, Jason R; Fowler, Nathan; Samaniego, Felipe; Steiner, Raphael; Nair, Ranjit; Iyer, Swaminathan P; Nav...
Journal:
Lancet oncology
Issue:
Volume 23:Issue 3(2022)
Page Start:
406
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search